Education
About Us
Working with TipRanks
Follow Us
Mesoblast Limited (AU:MSB)
ASX:MSB
MSB Stock Chart & Stats
AU$2.01
-AU$0.15(-5.07%)
At close: 4:00 PM EST
AU$2.01
-AU$0.15(-5.07%)
Day’s Range― - ―
52-Week RangeAU$1.52 - AU$3.31
Previous CloseN/A
Volume5.54M
Average Volume (3M)4.33M
Market Cap
AU$2.59B
Enterprise ValueAU$1.85B
Total Cash (Recent Filing)AU$161.16M
Total Debt (Recent Filing)AU$128.16M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,290,302,200
10 Day Avg. Volume4,518,407
30 Day Avg. Volume4,325,729
Financial Highlights & Ratios
PEG Ratio-27.18
Price to Book (P/B)2.09
Price to Sales (P/S)72.48
P/FCF Ratio-24.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.84Price Target Upside91.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$127.12M
Bulls Say, Bears Say
Bulls Say
Commercial Launch & Revenue GrowthA 191% YoY revenue surge driven by the Ryoncil commercial launch demonstrates early product-market fit and tangible commercial execution. Durable revenue from an approved cell therapy provides a foundation to scale sales, justify further label expansions, and attract partners needed for broader commercialization.
Very High Gross MarginA 90% gross margin indicates highly favorable unit economics for Mesoblast's cell therapy sales, supporting scalable profitability as volumes rise. Sustained high margins can finance commercial expansion and R&D, improving long-term return potential if manufacturing and supply costs remain controlled.
Strong LiquidityHaving $162M in cash provides meaningful runway to support commercial rollout, pivotal trials, and label-extension programs without immediate financing. Combined with low reported leverage, this liquidity reduces short-term refinancing risk and enables strategic investments in marketing and trial execution.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow means core operations are not yet self-funding, increasing reliance on cash reserves, debt, or equity raises to sustain the commercial build and trials. This structural cash gap can pressure capital structure and lead to dilution or constrained investment flexibility.
Persistent Net Losses / Negative ROENegative ROE and ongoing net losses indicate the company is not generating returns on shareholder capital. Until Mesoblast converts revenue momentum into positive net income, shareholder value depends on successful scaling and margin leverage; prolonged losses risk capital depletion or repeated financing.
Rising Operating ExpensesA material increase in SG&A from the commercial launch raises the firm's fixed cost base and break-even threshold. If revenue growth slows or takes longer to scale, elevated operating expenses will accelerate cash burn and pressure margins, requiring sustained top-line momentum to justify the commercial investment.
Mesoblast Limited News
MSB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest share price was AU$1.51 and its highest was AU$3.31 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is AU$2.59B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 181 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.034.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is >-0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,290,302,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -AU$0.044 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -7.589%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in AU:MSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.84 (91.23% Upside)
AU$3.84 (91.23% Upside)
Blogger Sentiment
Bullish
AU:MSB Sentiment 96%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
-18.95%
Trailing 12-Months
Asset Growth
17.27%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MSB Company Deck
MSB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive trajectory for Mesoblast, driven by the successful commercial launch of Ryoncil and significant revenue growth. Despite increased expenses and some regulatory challenges, the company shows robust market potential and financial health.View all AU:MSB earnings summariesMSB Stock 12 Month Forecast
Average Price Target
AU$3.84
▲(91.23% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Neuren Pharmaceuticals Limited
―
Orthocell Ltd
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Options Prices
Currently, No data available
---